Puma Biotechnology Inc. Stock
€3.54
Your prediction
Puma Biotechnology Inc. Stock
Puma Biotechnology is a publicly traded biopharmaceutical company that develops innovative cancer therapies targeting the most aggressive and difficult-to-treat forms of the disease. Puma's lead product is Nerlynx, an oral medication approved for the treatment of HER2-positive breast cancer, and the company also has a number of other promising drugs in its pipeline. Founded in 2010, Puma is headquartered in Los Angeles, California, and its shares trade on the NASDAQ exchange under the ticker symbol PBYI.
Pros and Cons of Puma Biotechnology Inc. in the next few years
Pros
Cons
Performance of Puma Biotechnology Inc. vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| Puma Biotechnology Inc. | 2.560% | -3.800% | -22.007% | 16.197% | -9.245% | -59.057% | - |
| Ardelyx Inc. | 3.070% | 1.608% | 5.441% | 102.500% | 9.308% | 7.085% | - |
| Evolus Inc | - | 0.000% | 7.477% | 37.725% | 27.072% | 32.948% | - |
| Salarius Pharmaceuticals Inc. | - | -3.015% | -6.311% | -66.724% | -30.450% | -98.501% | -99.994% |
News
Puma Biotechnology Announces Presentation of Findings from a Phase II Study of Alisertib in Endocrine-Resistant Metastatic Breast Cancer (TBCRC 041)
Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, announced the presentation of biomarker findings from a Phase II randomized clinical trial of alisertib alone vs. alisertib +
Puma Biotechnology to Join Russell 3000 Index
Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, is set to join the broad-market Russell 3000® Index at the conclusion of Russell Investments’ annual reconstitution of its
Puma Biotechnology Announces Publication of Alisertib Abstract Titles for the 2024 ASCO Annual Meeting
Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, announced the release of abstracts on alisertib to be presented at the 2024 American Society of Clinical Oncology (ASCO) Annual